Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib vs Capecitabine in Metastatic Colorectal Cancer
NCT00514761Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2006
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of selumetinib in metastatic colorectal cancer (mCRC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression event count. Started Sep 2006; status: completed.
02
Drugs
selumetinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00514761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00514761.